Redhill Biopharma (STU:2RH) Beneish M-Score: 0.00 (As of Jun. 25, 2026)

What is Redhill Biopharma Beneish M-Score?

Redhill Biopharma STU:2RH 18 Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Redhill Biopharma ranks worse than 109769.37% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Redhill Biopharma's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Redhill Biopharma was 30.81. The lowest was -3.98. And the median was -1.81.

Redhill Biopharma Beneish M-Score Related Terms

Redhill Biopharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Redhill Biopharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redhill Biopharma Beneish M-Score Chart

Redhill Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

-3.27

-3.98

0.00

Redhill Biopharma Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Beneish M-Score	Get a 7-Day Free Trial															0.00	10.88	0.00	0.00	0.00

STU:2RH vs LVRLF, BUDZ, GELS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Redhill Biopharma Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Beneish M-Score falls into.

Save Embed

18GF Score

Redhill Biopharma Ltd STU:2RH

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Redhill Biopharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Redhill Biopharma for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Dec25) TTM:

Last Year (Dec24) TTM:

Total Receivables was €2.12 Mil.
Revenue was €0.24 Mil.
Gross Profit was €0.24 Mil.
Total Current Assets was €5.58 Mil.
Total Assets was €21.65 Mil.
Property, Plant and Equipment(Net PPE) was €0.94 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.35 Mil.
Selling, General, & Admin. Expense(SGA) was €5.27 Mil.
Total Current Liabilities was €16.42 Mil.
Long-Term Debt & Capital Lease Obligation was €0.77 Mil.
Net Income was €-0.37 Mil.
Gross Profit was €0.99 Mil.
Cash Flow from Operations was €-8.24 Mil.

Total Receivables was €3.41 Mil.
Revenue was €0.00 Mil.
Gross Profit was €4.63 Mil.
Total Current Assets was €11.38 Mil.
Total Assets was €17.23 Mil.
Property, Plant and Equipment(Net PPE) was €0.42 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.59 Mil.
Selling, General, & Admin. Expense(SGA) was €4.67 Mil.
Total Current Liabilities was €21.22 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(2.117 / 0.244)	/	(3.406 / 0)
	=	8.67623	/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(4.633 / 0)	/	(0.244 / 0.244)
	=		/	1
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (5.575 + 0.944) / 21.645)	/	(1 - (11.375 + 0.417) / 17.231)
	=	0.698822	/	0.315652
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0.244	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.591 / (0.591 + 0.417))	/	(0.349 / (0.349 + 0.944))
	=	0.58631	/	0.269915
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(5.271 / 0.244)	/	(4.667 / 0)
	=	21.602459	/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.769 + 16.415) / 21.645)	/	((0.003 + 21.223) / 17.231)
	=	0.793902	/	1.23185
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-0.366 - 0.991	-	-8.242)	/	21.645
	=	0.318087

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 0.00 mean?

Redhill Biopharma (STU:2RH) has a Beneish M-Score of 0.00 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Redhill Biopharma and its competitors. According to the industry distribution chart, Redhill Biopharma ranks #999999 out of 911 companies in the Drug Manufacturers industry.

Is Redhill Biopharma's Beneish M-Score too high?

Redhill Biopharma's current Beneish M-Score is 0.00. Based on the distribution chart, Redhill Biopharma ranks #999999 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.

How does Redhill Biopharma's Beneish M-Score compare to LVRLF and BUDZ?

According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #999999 out of 911 companies for Beneish M-Score. This places Redhill Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Drug Manufacturers company?

A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Redhill Biopharma and its competitors. Redhill Biopharma's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Redhill Biopharma stock overvalued right now?

Redhill Biopharma (STU:2RH) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redhill Biopharma Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies LVRLF BUDZ GELS INM CVSI CTTH SBFM SNOA SHPH SXTC XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges RDHL:USA

Address 21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website https://www.redhillbio.com

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

18GF Score

Get the complete analysis for STU:2RH

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.24

Price

View STU:2RH Analysis

See Beneish M-Score data for all stocks →